61 Health Care companies Torvanta covers, sorted by their average factor grade, with revenue growth, P/E and operating margin from their SEC filings. Each grade compares a company with the rest of the sector.
| Company | Value | Growth | Profitability | Momentum | Revenue growth | P/E | Operating margin |
|---|---|---|---|---|---|---|---|
| INCY Incyte | A- | A+ | A | C | +21% | 16.1x | 30.0% |
| DXCM DexCom | C | A | B+ | B+ | +16% | 34.5x | 22.9% |
| LLY Eli Lilly | C- | A+ | A+ | C | +50% | 38.4x | n/a |
| BMY Bristol-Myers Squibb | A | C+ | B+ | C+ | +3% | 13.0x | n/a |
| AMGN Amgen | C+ | B- | A- | B | +9% | 25.0x | 30.0% |
| SOLV Solventum | B+ | C+ | B- | B | -1% | 10.8x | 25.0% |
| HCA HCA Healthcare | A- | B | – | C- | +7% | 15.0x | n/a |
| ABBV AbbVie | D+ | B | A- | B | +10% | 75.1x | 26.2% |
| CAH Cardinal Health | – | B- | – | B- | +19% | n/a | 1.0% |
| BIIB Biogen | B | D | B | B+ | +1% | 24.0x | n/a |
| DVA DaVita | A | B- | C+ | D+ | +6% | 14.7x | 15.2% |
| UHS Universal Health | A | C+ | C+ | C- | +10% | 7.2x | 11.4% |
| VEEV Veeva Systems | D | B+ | B+ | B- | +17% | 46.4x | 29.9% |
| VRTX Vertex | C- | B- | A | C | +10% | 29.3x | 38.0% |
| A Agilent | D+ | B- | B- | B+ | +9% | 33.8x | 22.2% |
| BSX Boston Scientific | B+ | B | B | D- | +14% | 17.2x | 19.8% |
| CI Cigna | A | B | C- | D+ | +8% | 11.2x | 3.5% |
| DGX Quest Diagnostics | B- | C+ | C | B | +10% | 24.7x | 14.1% |
| MCK McKesson | B- | B | C- | B- | +9% | 24.5x | 1.6% |
| WST West Pharmaceutical | D | B | B- | B+ | +12% | 48.2x | 20.5% |
| COR Cencora | B | B | C | C- | +5% | 23.4x | 0.9% |
| IQV IQVIA | C | C | C+ | B+ | +7% | 33.0x | 13.2% |
| MDT Medtronic | B | B- | C+ | C- | +10% | 21.6x | 18.1% |
| VTRS Viatris | A- | C- | D | B+ | +4% | n/a | -0.6% |
| ZTS Zoetis | A- | C- | A- | D- | +1% | 11.8x | n/a |
| CVS CVS Health | A- | B | D+ | D+ | +7% | 22.9x | 2.0% |
| ILMN Illumina, Inc. | D- | D | B+ | A+ | +5% | 54.8x | 19.6% |
| JNJ Johnson & Johnson | C | C | B | C+ | +8% | 29.3x | n/a |
| MRNA Moderna | – | – | F | A+ | -28% | n/a | -149.0% |
| PODD Insulet | B- | B+ | B | F | +29% | 25.4x | 16.9% |
| REGN Regeneron | C+ | C- | B | C+ | +9% | 18.0x | 24.7% |
| RMD ResMed | B- | C | B+ | D+ | +10% | 21.4x | 33.4% |
| BAX Baxter | B+ | B- | D | C | +5% | n/a | -2.4% |
| ELV Elevance Health | B+ | C- | C | C | +6% | 17.5x | 2.7% |
| HSIC Henry Schein | B- | C+ | C- | C+ | +6% | 24.6x | 5.0% |
| MTD Mettler-Toledo | D+ | C | C+ | B+ | +7% | 34.7x | n/a |
| TECH Bio-Techne | D+ | B- | C+ | B- | -0% | 63.1x | 20.7% |
| TMO Thermo Fisher | D | C+ | C | A- | +7% | 36.4x | 17.6% |
| GILD Gilead | – | C- | C | B | +6% | n/a | -8.2% |
| COO Cooper Companies | B+ | B | C- | D- | +5% | 19.4x | 12.8% |
| IDXX IDEXX | D+ | B | A- | D- | +13% | 37.0x | 32.0% |
| ISRG Intuitive Surgical | D | B+ | B+ | D | +21% | 46.6x | 31.3% |
| LH Labcorp | B- | C+ | D+ | C+ | +6% | 25.5x | 10.4% |
| ZBH Zimmer Biomet | B | C | C | C- | +9% | 22.2x | 14.2% |
| RVTY Revvity | D | D+ | C- | A+ | +4% | 75.3x | 12.3% |
| SYK Stryker | C | B | B- | D- | +8% | 29.6x | 21.4% |
| CNC Centene | – | B- | D- | B- | +14% | n/a | -2.8% |
| DHR Danaher | D+ | C+ | C | C+ | +5% | 39.3x | 20.4% |
| EW Edwards Lifesciences | D | C+ | B | C- | +15% | 50.1x | 22.3% |
| GEHC GE HealthCare | B+ | D+ | C | D+ | +6% | 15.7x | 12.6% |
| STE Steris | B- | C | C | D+ | +8% | n/a | 18.9% |
| MRK Merck | D | D | B- | B | +5% | 110.7x | n/a |
| PFE Pfizer | C | D- | C+ | B- | -0% | 36.1x | n/a |
| UNH UnitedHealth | C+ | D+ | C+ | D+ | +6% | 24.3x | 4.8% |
| ALGN Align Technology | C+ | D+ | C+ | D | +4% | 24.5x | 13.2% |
| WAT Waters | F | C- | D+ | A- | +55% | 109.8x | 7.1% |
| BDX Becton Dickinson | C- | D- | D+ | B | -3% | 54.4x | 9.6% |
| HUM Humana | D+ | D+ | D | B | +14% | 43.1x | 1.8% |
| ABT Abbott Labs | C- | D+ | C | D+ | +7% | 28.0x | 17.1% |
| CRL Charles River | D- | F | D | A+ | -1% | n/a | 2.3% |
| MOH Molina Healthcare | D | D- | D- | D | +3% | n/a | 0.5% |
Subscribers get the model's rank and expected return for every covered company, the reasoning behind each, and the Torvanta model portfolio's trades each trading day, sized and explained, at three risk levels.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer